Cystic Fibrosis
As touchRESPIRATORY approaches 10 years of providing education for busy respiratory specialists, we are looking to the future—and it certainly looks bright!
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
As part of our Future Leaders series, we speak with Dr Helen Gavillet, a post-doctoral researcher at Northumbria University (UK) and Rising Star at RTI 2025. Dr Gavillet's research focuses on the lung microbiome in cystic fibrosis, particularly bacterial and fungal dynamics. Her research also examines the impact of CFTR modulators like elexacaftor/tezacaftor/ivacaftor on respiratory microbiota.
A recent single-arm, phase 3 study (RIDGELINE VX21-121-105)1 published in The Lancet Respiratory Medicine2 has shown positive results for vanzacaftor–tezacaftor–deutivacaftor in treating paediatric cystic fibrosis (CF) patients, demonstrating improvements in lung function, sweat chloride levels and quality of life. This trial focused on children aged 6 to 11 years, a group often excluded from studies involving adults or older children, as well as key ages for CF treatment.
It was a pleasure to speak with Dr Molla Imaduddin Ahmed (Leicester Childrens' Hospital, Leicester, UK) around his abstract on ‘The impact of Symkevi (Tezacaftor/Ivacaftor) on exercise capacity in adolescents with CF.', which was presented at ERS International ...
It was great to talk with Dr Molla Imaduddin Ahmed (Leicester Childrens' Hospital, Leicester, UK) around the impact of CFTR modulator therapies and exciting advances in the treatment of cystic fibrosis. Questions What has been the impact of cystic fibrosis ...
TouchRESPIRATORY got the opportunity to catch up with Dr Jordana E Hoppe (Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, US) to discuss the phase 3 extension study of lumacaftor–ivacaftor therapy in young children with cystic fibrosis ...
Dr Jennifer Taylor-Cousar (National Jewish Health, Denver, CO, USA) explores what we have learnt so far about how COVID-19 is effecting patients with cystic fibrosis. Questions 1. What is the risk to cystic fibrosis patients from COVID-19 and what have we ...
Cystic fibrosis (CF), an inherited disease affecting all races and ethnicities, results from defects in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which leads to dysregulations in the ion and fluid balance across epithelial membranes throughout the body.1–3 The ...
Welcome to the latest edition of US Respiratory & Pulmonary Diseases, which features a diverse range of articles reflecting the wide spectrum of respiratory disease. We begin with a focus on chronic obstructive pulmonary disease (COPD), the third leading cause ...
Welcome to the latest edition of European Respiratory & Pulmonary Diseases. The past decade has seen numerous advances in the field of respiratory care, and yet respiratory disease remains a leading cause of death and disability worldwide. This edition features ...
Cystic fibrosis (CF) is caused by mutations in a single gene; treatment burden is high and life expectancy is significantly shortened (median age of survival in the UK is ~40 years). Although CF is a multi-organ disease, chronic lung infection and ...
Case Presentation The patient described was diagnosed with cystic fibrosis (CF) at 2 years of age. She was pancreatic insufficient and had an F508del homozygous genotype. Her pretransplant CF-course was complicated by CF-related diabetes, chronic sino-pulmonary colonization with Pseudomonas aeruginosa (...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
